SOUTH SAN FRANCISCO, Calif., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will present at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8 at 11:30 AM (EST). Julie Hambleton, Chief Medical Officer, and Marc Belsky, Chief Financial Officer, will present an overview of the company at the conference. The conference will be held in New York City.
The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or directly at http://www.veracast.com/webcasts/opco/healthcare2015/11107475824.cfm. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Amy Kendall, Corporate Communications 415-365-5776 email@example.com
Source:Five Prime Therapeutics, Inc.